Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms 183Breast Neoplasms 174Carcinoma, Non-Small-Cell Lung 173Colorectal Neoplasms 105Stomach Neoplasms 81Pancreatic Neoplasms 79Lung Neoplasms 79Prostatic Neoplasms 77Melanoma 68Neoplasm Metastasis 67Recurrence 66Leukemia, Myeloid, Acute 66Multiple Myeloma 64Ovarian Neoplasms 62Carcinoma, Hepatocellular 62Lymphoma 61Advanced Solid Tumor 61Advanced Solid Tumors 56Solid Tumor 50Uterine Cervical Neoplasms 48Lymphoma, Non-Hodgkin 48Glioblastoma 44Lymphoma, B-Cell 40Leukemia 39Colonic Neoplasms 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Head and Neck Neoplasms 33Esophageal Neoplasms 32Urinary Bladder Neoplasms 30Sarcoma 30

Interventions

Paclitaxel 1Gemcitabine 1Drug Evaluation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × INDUSTRY × Serous Ovarian Cancer × Clear all
NCT06055348 2023-09-26

SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer

Biocity Biopharmaceutics Co., Ltd.

Phase 1/2 Unknown
112 enrolled
Gynecologic

Serous Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡